Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?

European Heart Journal

Volumn 30, Issue 11, 2009, Pages 1301-1304

  Bartnik, Małgorzata ^a   Cosentino, Francesco ^b  

^a SKARABORG HOSPITAL   (Sweden)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DISEASE COURSE; DYSGLYCAEMIA; EDITORIAL; EVIDENCE BASED MEDICINE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; AGED; DIABETIC ANGIOPATHY; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; NOTE; RISK FACTOR;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; RISK FACTORS;

EID: 67651121926     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp168     Document Type: Editorial

References (27)

1. Dale AC, Midthjell K, Nilsen Tl, Wiseth R, Vatten LJ. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT Study in Norway. Eur Heart J 2009; 30:1372-1377. First published on 20 February 2009. doi:10.1093/eurheartj/ ehp039.
2. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006; 368:1651-1659.
3. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standi E, Soler-Soler J, Öhrvik J, on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004; 25:1880-1890.
4. Levine SA. Angina pectoris. Some clinical considerations. JAMA 1922; 79:928-933.
5. Cosentino F, Rydén L, Francia P. Diabetes and the metabolic syndrome. In: Camm AJ, Lüscher TF, Serruys PW eds. ESC Textbook of Cardiovascular Disease. 2nd edn, 2009, in press.
6. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase H, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell Ch, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thorn T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y; the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119;e21-e181
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a m eta regression analysis of of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233-240.
8. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 3554: 617-621.
9. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
10. Rydén L, Standi E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M-J, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Östergren J, Tuomilehto J, Thrainsdottir I. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
11. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention program. Diabet Med 2007; 24:137-144.
12. Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359:2140-2144.
13. Bartnik M, Malmberg K, Norhammar A, Tenerz Å, Öhrvik J, Rydén L Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004; 25:1990-1997.
14. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
15. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49:1761-1769.
16. Ga; de P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
17. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Bach P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk A population study of 3.3 milion people. Circulation 2008; 117:1945-1954.
18. Anselmino M, Öhrvik J, Malmberg K, Standi E, Ryden L, on behalf of the Euro Heart Survey Investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008; 29:177-184.
19. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 12; 358:2545-2559.
20. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
21. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-139.
22. Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes (UKPDS 80). N Engl] Med 2008; 359:1577-1589.
23. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gift AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32:381-386.
24. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2001; 321:412-419.
25. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155:26-32.
26. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008; 156:623-632.
27. Acarbose Cardiovascular Evaluation Trial (ACE), www.clinicaltrials.gov/ ct2/show/NCT00829660.